Información:
Error:
ID
34287
Descripción
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01486966
Link
https://clinicaltrials.gov/show/NCT01486966
Palabras clave
Versiones (1)
- 16/1/19 16/1/19 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
16 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Diabetes NCT01486966
Eligibility Diabetes NCT01486966
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT01486966
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
type 2 diabetes mellitus (diagnosed clinically) for at 12 months or longer
boolean
ID.2
Item
currently treated with basal insulin once daily or premixed insulin twice daily for at least 3 months with or without oad(s), and total daily insulin dose less than 1.4 iu (u)/kg (if treated with metformin, unchanged total daily dose of at least 1000 mg for at least 3 months)
boolean
ID.3
Item
body mass index (bmi) equal to 40 kg/m^2 or below
boolean
ID.4
Item
hba1c (glycosylated haemoglobin a1c) between 7.0% and 10.0% by central laboratory analysis
boolean
ID.5
Item
plan to be admitted for optimising glycaemic control at least 2 days prior to the randomisation
boolean
ID.6
Item
treatment with thiazolidinediones (tzd) or glucagon-like peptide-1 (glp-1) receptor agonists within the last 3 months prior to the screening
boolean
ID.7
Item
anticipated change after the randomisation in concomitant medication known to interfere with glucose metabolism, such as systemic corticosteroids, beta-blockers and mono amine oxidase (mao) inhibitors
boolean
ID.8
Item
previous participation in this trial (participation is defined as randomised. re-screening of screening failures is allowed only once within the limits of the recruitment period.)
boolean